TY - ECHAP KW - Neglected tropical diseases (NTDs) KW - Leishmaniasis KW - Chagas disease KW - Trypanosomiasis KW - Treatment KW - Benznidazole KW - Chemotherapy KW - Clinical trials KW - drug development KW - Drug repurposing KW - Drug Resistance KW - Glucantime KW - Leishmania spp. KW - Medicinal chemistry KW - New pharmaceuticals KW - New treatment schemes KW - Pentavalent antimonials KW - Pentostam KW - Side effects KW - Trypanosoma cruzi KW - Trypanosomatids AU - Accioly Brelaz de Castro MC AU - Silva AC AU - Ramos dos Santos TA AU - Costa Oliveira CN AU - Silva de Morais RC AU - Paiva-Cavalcanti M AU - Alves Pereira VR AB -

Leishmaniasis and trypanosomiasis are challenges among neglected tropical diseases. They usually affect marginal and poor populations and have the potential of becoming lethal. Current treatment for both diseases is based on chemotherapy, with the drug of choice being pentavalent antimonials for leishmaniasis, while for Chagas disease the two nitro-heterocyclic drugs, Benznidazole and Nifurtimox are recommended. The limited number, low efficacy, and side effects of conventional anti-Leishmania and anti-Trypanosomal drugs and the resistance developed by parasites are the major factors responsible for the growth in mortality rates. Currently there is an urgent need to develop effective, safe, cost-effective drugs, and new treatment schemes, as well as vaccines. As a result, international health organizations, universities, foundations, and pharmaceutical corporations are working together to support analysis and development of new strategies for controlling these diseases.

BT - Tropical Diseases: An Overview of Major Diseases Occurring in the Americas DO - 10.2174/9781681085876117010110.2174/9781681085876117010007 LA - eng N2 -

Leishmaniasis and trypanosomiasis are challenges among neglected tropical diseases. They usually affect marginal and poor populations and have the potential of becoming lethal. Current treatment for both diseases is based on chemotherapy, with the drug of choice being pentavalent antimonials for leishmaniasis, while for Chagas disease the two nitro-heterocyclic drugs, Benznidazole and Nifurtimox are recommended. The limited number, low efficacy, and side effects of conventional anti-Leishmania and anti-Trypanosomal drugs and the resistance developed by parasites are the major factors responsible for the growth in mortality rates. Currently there is an urgent need to develop effective, safe, cost-effective drugs, and new treatment schemes, as well as vaccines. As a result, international health organizations, universities, foundations, and pharmaceutical corporations are working together to support analysis and development of new strategies for controlling these diseases.

PB - BENTHAM SCIENCE PUBLISHERS PY - 2017 SE - 4 EP - 15 T2 - Tropical Diseases: An Overview of Major Diseases Occurring in the Americas TI - Leishmaniasis and Chagas disease treatment. UR - https://tinyurl.com/y8oz9bcl ER -